Unraveling the nexus: Tumor mutational burden, PD‐L1 expression, and oncogenic alterations in non–small cell lung cancer cytology specimens
These findings demonstrate distinct TMB and PD-L1 profiles that may identify patients who will benefit from ICI therapy. Cytology specimens provide adequate material for biomarker testing, which underscores their value in guiding immunotherapy decisions.
Authors
- Gökçe Törüner (ORCID: https://orcid.org/0000-0002-5305-6337)
- Gloria Hopkins Sura (ORCID: https://orcid.org/0000-0003-4817-458X)
- Hyvan Dang
- Mark J. Routbort (ORCID: https://orcid.org/0000-0003-4860-261X)
- Richard K. Yang (ORCID: https://orcid.org/0000-0003-0433-8626)
- Shun Rao (ORCID: https://orcid.org/0000-0002-2081-6491)
- Leomar Y. Ballester (ORCID: https://orcid.org/0000-0002-6854-6830)
- Min Dai (ORCID: https://orcid.org/0000-0003-3680-365X)
- Rajyalakshmi Luthra (ORCID: https://orcid.org/0000-0002-7133-0221)
- F. Anthony San Lucas
- K. J. Sweeney
- P. Wei
- Keyur P. Patel
- Hui Chen
- Sinchita Roy‐Chowdhuri
- Asif Rashid
- Hector Alvarez
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Cancer Cytopathology
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1002/cncy.70090
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00